Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy.

[1]  A. Tamori,et al.  Clinical significance of pretreatment serum interferon‐gamma‐inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir‐based triple therapy , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  K. Matsuura,et al.  Serum interferon‐gamma‐inducible protein‐10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  R. Molenkamp,et al.  IP-10 in chronic hepatitis C patients treated with high-dose interferon. , 2014, The Netherlands journal of medicine.

[4]  M. Honda,et al.  Hepatic interferon‐stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin‐28B genotypes , 2014, Hepatology.

[5]  E. Ferrannini,et al.  Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. , 2014, Autoimmunity reviews.

[6]  A. Tsubota,et al.  Impact of IL28B polymorphisms on 24‐week telaprevir‐based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b , 2014, Journal of gastroenterology and hepatology.

[7]  T. Asselah,et al.  Genomics and HCV infection: progression of fibrosis and treatment response. , 2012, Journal of hepatology.

[8]  N. Enomoto,et al.  Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response , 2012, Hepatology.

[9]  C. Rui.  Genetic variation in IL-28B and spontaneous clearance of hepatitis C virus , 2012 .

[10]  N. Hayashi,et al.  Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. , 2012, Journal of hepatology.

[11]  Jean-Michel Pawlotsky,et al.  Antiviral strategies in hepatitis C virus infection. , 2012, Journal of hepatology.

[12]  Michael Adler,et al.  Response-guided telaprevir combination treatment for hepatitis C virus infection. , 2011, The New England journal of medicine.

[13]  Yusuke Nakamura,et al.  IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. , 2011, The Journal of infectious diseases.

[14]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[15]  J. Hibbert,et al.  CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications , 2011, Cytokine & growth factor reviews.

[16]  H. Nomura,et al.  The rs8099917 Polymorphism, When Determined by a Suitable Genotyping Method, Is a Better Predictor for Response to Pegylated Alpha Interferon/Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28B , 2011, Journal of Clinical Microbiology.

[17]  A. Neumann,et al.  Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms , 2011, PloS one.

[18]  K. Shianna,et al.  Quantitation of pretreatment serum interferon‐γ–inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response , 2011, Hepatology.

[19]  H. Nomura,et al.  The rs 8099917 Polymorphism , When Determined by a Suitable Genotyping Method , Is a Better Predictor for Response to Pegylated Alpha Interferon / Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28 B † , 2011 .

[20]  Yusuke Nakamura,et al.  Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin , 2010, Hepatology.

[21]  A. Neumann,et al.  Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C , 2010, Hepatology.

[22]  M. Manns,et al.  Telaprevir for previously treated chronic HCV infection. , 2010, The New England journal of medicine.

[23]  Sven Bergmann,et al.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.

[24]  Jean-Michel Pawlotsky,et al.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.

[25]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[26]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[27]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[28]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[29]  G. Everson,et al.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.

[30]  C. Sarrazin,et al.  Treatment predictors of a sustained virologic response in hepatitis B and C. , 2008, Journal of hepatology.

[31]  M. Calvino,et al.  The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. , 2007, Journal of hepatology.

[32]  M. Cam,et al.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response , 2007, Hepatology.

[33]  A. Neumann,et al.  IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection , 2006, Hepatology.

[34]  A. Neumann,et al.  Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. , 2006, The Journal of infectious diseases.

[35]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[36]  Andrew H Talal,et al.  Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. , 2005, Blood.

[37]  Yoshiyuki Suzuki,et al.  Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy , 2005, Intervirology.

[38]  Rakesh K. Kumar,et al.  Expression of the chemokine IP‐10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation , 2003, Journal of leukocyte biology.

[39]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[40]  J. Hoofnagle.  Course and outcome of hepatitis C , 2002, Hepatology.

[41]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[42]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[43]  O. Bagasra,et al.  The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. , 1997, Cytokine & growth factor reviews.

[44]  Y. Tominaga,et al.  Expression of IFN-inducible protein-10 in chronic hepatitis. , 1997, Journal of immunology.

[45]  Andrew D. Luster,et al.  γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins , 1985, Nature.